Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Active Hexose-correlated Compound Down-regulates HSP27 of Pancreatic Cancer Cells, and Helps the Cytotoxic Effect of Gemcitabine

SHIGEYUKI SUENAGA, YASUHIRO KURAMITSU, SEIJI KAINO, SHIN-ICHIRO MAEHARA, YOSHIHIKO MAEHARA, ISAO SAKAIDA and KAZUYUKI NAKAMURA
Anticancer Research January 2014, 34 (1) 141-146;
SHIGEYUKI SUENAGA
1Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
2Department of Hepatology and Gastroenterology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUHIRO KURAMITSU
1Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: climates@yamaguchi-u.ac.jp
SEIJI KAINO
2Department of Hepatology and Gastroenterology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIN-ICHIRO MAEHARA
3Department of Surgery and Science, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIHIKO MAEHARA
3Department of Surgery and Science, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ISAO SAKAIDA
2Department of Hepatology and Gastroenterology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUYUKI NAKAMURA
1Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Active hexose-correlated compound (AHCC), an extract of basidiomycete mushroom, is used as health food to enhance the therapeutic effects and reduce the adverse effects of chemotherapy. Our previous proteomic analysis revealed that up-regulation of heat-shock protein 27 (HSP27) was responsible for gemcitabine resistance of pancreatic cancer cells. The aim of the present study was to investigate the effect of AHCC on the expression of HSP27 and the effect of combinatorial treatment of AHCC and gemcitabine on the gemcitabine-resistant pancreatic cancer cell line KLM1-R. Materials and Methods: KLM1-R cells were treated with AHCC, and the expression of HSP27 as well as the cytotoxic effects of combinatorial treatment of AHCC and gemcitabine were investigated with western blotting and MTS assay, respectively. Results: AHCC down-regulated HSP27 and exhibited a cytotoxic effect on KLM1-R cells. Furthermore, the cytotoxic effect of the combinatorial treatment of AHCC and gemcitabine was synergistic. Conclusion: This study supports the potential therapeutic benefits of combinatorial treatment of AHCC and gemcitabine for patients with pancreatic cancer.

  • Active hexose-correlated compound
  • heat-shock protein 27
  • pancreatic cancer
  • gemcitabine

Pancreatic cancer is associated with poor prognosis and a 5-year survival rate of less than 5%. Pancreatic cancer is the fifth most common cause of cancer deaths worldwide (1). Surgical resection is the only curative treatment, but most patients are diagnosed with disease at an advanced, unresectable stage. In addition, the lack of effective systemic treatment associated with a dismal prognosis (2-4).

Gemcitabine (2’-deoxy-2’,2’-difluorocytidine monohydrochloride; Gemzar®) is a deoxycytidine analog with structural and metabolic similarities to cytarabine. Gemcitabine has long been used as the therapeutic standard drug for many patients with pancreatic cancer, since gemcitabine improved quality of life in a subset of patients and moderately extended survival (5-8). However, intrinsic or acquired resistance of pancreatic cancer disturbs the therapeutic effect of gemcitabine (9, 10).

Our previous studies investigated proteomic expression in gemcitabine-resistant and -sensitive human pancreatic adenocarcinoma cell lines. Expressions of many proteins were different between gemcitabine-resistant and -sensitive cell lines, and liquid chromatography-tandem mass spectrometry and western blotting identified heat-shock protein 27 (HSP27) as being up-regulated in the gemcitabine-resistant cell lines (11, 12). Further experiments showed that HSP27 plays an important role in gemcitabine resistance, because knock-down or down-regulation of HSP27 in gemcitabine-resistant cells increased the cytotoxic effect of gemcitabine (13-15).

Active hexose-correlated compound (AHCC) is a mixture of polysaccharides, amino acids, lipids, and minerals derived from the culture of the basidiomycete mushroom Lentinula edodes. The predominant components of AHCC are oligosaccharides, of which major portions are α1,4-glucans with a molecular weight of around 5,000 Daltons. AHCC has been reported to have many health benefits, including both immunomodulatory and antitumor effects (16, 17). Several clinical studies showed that AHCC improved the prognosis and quality of life, and reduced adverse effects of chemotherapy of patients with head and neck cancer, advanced liver cancer and lung cancer (18-20).

There is no literature regarding the effect of AHCC on HSP expression or its effects on pancreatic cancer cells in vitro. In the present study, we investigated whether AHCC had an impact on expression of HSP families and the effect of combinatorial treatment of AHCC and gemcitabine on gemcitabine-resistant pancreatic cancer KLM1-R cells.

Materials and Methods

Cancer cell line and culture conditions. KLM1-R, gemcitabine-resistant pancreatic cancer cell line, was kindly provided by the Department of Surgery and Science, Kyushu University Graduate School of Medical Science. KLM1-R was established by exposing gemcitabine-sensitive KLM1 cells to gemcitabine, as previously described (21). This gemcitabine-resistant cell line did not exhibit any morphological changes, including spindle-shaped morphology and appearance of pseudopodia such as in epithelial-to-mesenchymal transition, compared to the parental cells (data not shown). The cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (inactivated at 56°C for 30 min), 2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), and 1.0 mM sodium pyruvate, and maintained in a humidified 5% carbon dioxide-95% air mixture at 37°C.

Agents. AHCC and cyclodextrin were kindly provided by Amino Up Chemical Co., Ltd. (Sapporo, Japan). Cyclodextrin is a diluting agent for AHCC, and it was used as a control. Gemcitabine was obtained from Eli Lilly Japan K. K. (Kobe, Japan).

Sample preparation. KLM1-R cells were treated with AHCC (0, 1, 5, 10 mg/ml) for 48 h. Cells were then homogenized in lysis buffer [50 mM Tris-HCl, pH 7.5, 165 mM sodium chloride, 10 mM sodium fluoride, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 mM ethylendiaminetetra-acetic acid (EDTA), 10 μg/ml aprotinin, 10 μg/ml leupeptin, and 1% nonyl phenoxypolyethoxylethanol-40 (NP-40)] on ice. Suspensions were incubated for 1 h at 4°C and centrifuged at 15,000 × g for 30 min at 4°C. The supernartants were collected and used for western blotting after protein concentrations were measured by Lowry method (22). The samples from KLM1-R cells were prepared three times independently.

Western blot analysis. Twenty micrograms of protein samples were used for western blot analysis. Sodium dodecyl sulfate-polyaclylamide gel electrophoresis (SDS-PAGE) was carried out in pre-cast gels (12% acrylamide; Mini-PROTEAN TGX Gels, Bio-Rad, Hercules, CA, USA). After electrophoresis, gels were transferred electrophoretically onto polyvinylidene difluoride membranes (Immobilon-P; Millipore, Bedford, MA, USA) and blocked overnight at 4°C with Tris-buffered saline (TBS) containing 5% skimmed milk. Primary antibodies were: mouse monoclonal antibody against HSP27 (dilution 1:200, #sc-13132 (F-4); Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal antibody against HSP60 (dilution 1:5000, ab46798; Abcam, Cambridge, MA, USA), goat polyclonal antibody against HSP70 (dilution 1:200, #sc-1060 (K-20); Santa Cruz Biotechnology), mouse monoclonal antibody against heat shock cognate 71 kDa protein (HSC70) (dilution 1:200, #sc-7298 (B-6); Santa Cruz Biotechnology), goat polyclonal antibody against 78 kDa glucose-regulated protein (GRP78) (dilution 1:200, #sc-1050 (N-20); Santa Cruz Biotechnology), and goat polyclonal antibody against actin (dilution 1:200, #sc-1616 (I-19); Santa Cruz Biotechnology). Membranes were incubated with the primary antibody overnight at 4°C, washed three times with TBS containing 0.05% Tween-20 and once with TBS, and then incubated with a horseradish peroxidase-conjugated secondary antibody (dilution 1:10,000; Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) for 1 h at room temperature. Bands of HSP27, HSP60, HSP70, HSC70, GRP78 and actin were visualized by enhanced chemiluminescence system (ImmunoStar Long Detection; Wako, Osaka, Japan), and recorded by using Image Reader LAS-1000 Pro (Fujifilm Corporation, Tokyo, Japan) (23-27). Expression levels of HSP27 and actin with and without AHCC treatment in KLM1-R cells were quantified by analyzing the intensity of each band with the Multi Gauge ver3.0 software (Fujifilm Corporation, Tokyo, Japan). Statistical significance of differences in expression levels of HSP27 with and without AHCC treatment in KLM1-R cells was calculated by one-way analysis of variance (ANOVA). A value of p<0.05 was considered to be statistically significant. The software application used was JMP 9 (SAS Institute Inc., Cary, NC, USA).

Cytotoxic effect of AHCC. Cells (2×103 cells per well) were seeded in complete medium in 96-well plates, and cultured for 24 h, and then exposed to different concentrations (0, 2, 4, 6, 8, 10 mg/ml) of AHCC or cyclodextrin for 72 h. After incubation, 20 μl of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega Co., Madison, WI, USA) solution was added to each well. After 2 h, the optical density of the dissolved material was measured at 490 nm with a microtiter plate reader (Model 550 Microplate Reader; Bio-Rad, Hercules, CA, USA). Results were derived from at least three independent sets of triplicate experiments. Statistical significance of differences in proliferation rate of KLM1-R cells treated with AHCC or cyclodextrin were calculated by Student's t-test. A value of p<0.05 was considered to be statistically significant.

Synergetic cytotoxic effect of AHCC and gemcitabine on KLM1-R cells. Cells (2×103 cells per well) were seeded in complete medium in 96-well plates, and cultured for 24 h, and then exposed to different concentrations (0 or 2 mg/ml) of AHCC for 48 h, and then treated with gemcitabine (0 or 25 ng/ml) for 72 h. After incubation, 20 μl of MTS solution was added to each well. After 2 h, the optical density of the dissolved material was measured at 490 nm with microtiter plate reader. Results were derived from at least three independent sets of triplicate experiments. Statistical analysis of the differences in the percentage of control cell growth with and without AHCC and gemcitabine treatment was performed using one-way or two-way ANOVA. A value of p<0.05 was considered to be statistically significant.

Results

The effect of AHCC on the HSP27 expression levels in KLM1-R cells. The intracellular proteins from KLM1-R cells were analyzed by western blotting with a primary antibody against HSP27, HSP60, HSP70, HSC70, GRP78 and actin. The protein expression of HSP27 was reduced by AHCC treatment in KLM1-R cells. On the other hand, the protein expression of HSP60, HSP70, HSC70, GRP78 and actin were the same in all cells (Figure 1).

The ratio of intensities of HSP27 to actin (HSP27/actin) in KLM1-R cells without AHCC treatment was considered 100%. HSP27/actin in KLM1-R cells treated with 1, 5 and 10 mg/ml AHCC was 88.7±6.6%, 71.5±0.9%, 48.6±1.6%, respectively. The results show that the HSP27 protein levels were reduced by AHCC in KLM1-R cells in a dose-dependent manner (Figure 2).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Expression levels of heat-shock protein (HSP) family proteins in KLM1-R cells treated with active hexose correlated compound (AHCC). Western blot analysis of HSP family proteins and actin in gemcitabine-resistant pancreatic cancer KLM1-R cells treated with AHCC (0, 1, 5, 10 mg/ml). The protein expression of HSP27 (bands of 27 kDa) was reduced by AHCC treatment in KLM1-R cells. On the other hand, protein expression of HSP60, HSP70, HSC70, GRP78 and actin were similar in all cells.

Cytotoxic effect of AHCC on KLM1-R cells. To investigate whether AHCC had a cytotoxic effect on KLM1-R cells, we added AHCC or cyclodextrin to the growth media and calculated the proliferation rate by the MTS assay. The proliferation rate of KLM1-R cells without AHCC or cyclodextrin as a control treatment was taken as 100%. The proliferation rate of KLM1-R cells treated with 2 and 4 mg/ml AHCC were 77.5±2.9% and 6.3±3.4%, respectively, and of cells treated with 6, 8 and 10 mg/ml AHCC was 0%. The proliferation rate of KLM1-R cells treated with 2, 4, 6, 8 and 10 mg/ml cyclodextrin were 97.9±8.4%, 95.6±7.3%, 85.4±7.3%, 90.2±15.7%, 87.5±11.3%, respectively. These results show that cyclodextrin did not affect the growth of the KLM1-R cells. In contrast, AHCC had a cytotoxic effect on KLM1-R cells (Figure 3).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

The intensity of the heat-shock protein-27 (HSP27)/actin bands in KLM1-R cells treated with active hexose correlated compound (AHCC). This graph shows the ratio of the intensities of HSP27 protein to actin protein bands in KLM1-R cells treated with AHCC. The intensities of HSP27/actin were significantly reduced by AHCC in KLM1-R cells in a dose-dependent manner (*p<0.01 by one-way ANOVA). A value of p<0.05 was considered statistically significant (n=3).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Cytotoxic effect of active hexose correlated compound (AHCC) on KLM1-R cells. The proliferation rates of KLM1-R cells treated with different concentrations of AHCC or cyclodextrin, a diluting agent, were calculated by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. This graph shows that cyclodextrin as a control did not affect the growth of KLM1-R cells. In contrast, AHCC exhibits a cytotoxic effect on KLM1-R cells (*p<0.01 by Student's t-test). p-Values indicate between AHCC-treatment and cyclodextrin-treatment at each concentration. A value of p<0.05 was considered to be statistically significant (n=6).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

The cytotoxic effect of the combinatorial treatment of active hexose correlated compound (AHCC) and gemcitabine (GEM) on KLM1-R cells. This graph shows the proliferation rates of gemcitabine-resistant KLM1-R cells treated with gemcitabine alone (25 ng/ml), AHCC (2 mg/ml) alone, combination of AHCC and gemcitabine or no-treatment. The cytotoxic effect of the combinatorial treatment of AHCC and gemcitabine was significantly higher compared to treatments with AHCC or gemcitabine-alone (*p<0.01 by one-way ANOVA). A value of p<0.05 was considered statistically significant.

The cytotoxic effect of AHCC and gemcitabine on KLM1-R cells. We examined the effect of combinatorial treatment with AHCC and gemcitabine on gemcitabine-resistant KLM1-R cells by the MTS assay. As shown in Figure 4, we calculated the proliferation rate of the cells treated with gemcitabine-alone, AHCC-alone, combination of AHCC and gemcitabine, or no treatment. The cytotoxic effect of the combinatorial treatment of AHCC and gemcitabine was significantly higher compared to the treatment with AHCC alone or gemcitabine alone (one-way ANOVA). Furthermore, two-way ANOVA showed that the effect of the combinatorial treatment was synergistic (p=0.0008).

Discussion

HSP27 is a member of the small heat-shock protein family and possesses chaperon-like activity, preventing aggregation of improperly-folded or partially-denatured proteins (28-30). HSP27 also regulates client proteins that are involved in the apoptotic pathway including protein kinase B (Akt), p53 and nuclear factor-kappa B (NF-κB) (31). Furthermore, many groups have reported that overexpression of HSP27 is associated with promoting drug resistance and poor prognosis in many types of cancer (32-40). Our previous studies revealed that the expression of HSP27 was up-regulated in a gemcitabine-resistant pancreatic cancer cell lines compared to gemcitabine-sensitive ones (11, 12). Hsu et al. reported that quercetin inhibited the expression of HSP27, and reduced the viability of lung cancer cells when used in a combinatorial treatment with either cisplatin or gemcitabine (41). Heinrich et al. reported that RP101 (bromovinyldeoxyuridine), inhibitor of HSP27 function, prevented resistance of rat sarcoma cells to cisplatin (42). These reports show that reduction of HSP27 might increase sensitivity to chemotherapy. In fact, our previous studies showed that interferon-γ or N-formyl-3,4-methylenedioxy-benzylidene-γ-butyrolactam (KNK437) down-regulated the expression of HSP27, and increased gemcitabine sensitivity in gemcitabine-resistant pancreatic cancer KLM1-R cells (13, 14).

AHCC has been extensively studied for safety in both patients with cancer and healthy volunteers (43-45). Several studies have investigated the alleviating effects of AHCC for chemotherapy-related side-effect. Nakamoto et al. reported that AHCC reduced hematological toxicity of gemcitabine in non-tumor-bearing mice (46). Sun et al. reported that AHCC reduced cytosine arabinoside-induced hair loss, and 6-mercaptopurin and methotrexate-induced liver injury in mice (47). Furthermore, AHCC also enhanced the chemotherapeutic effects of UFT (tegafur and uracil in a 4:1 molar concentration) for mammary adenocarcinoma SST-2 cells in rats (48), and cisplation for Colon-26 tumor cells in mice (49).

The present study showed that AHCC down-regulated the expression of HSP27, and combinatorial treatment of AHCC and gemcitabine synergistically increased the cytotoxic effect on gemcitabine-resistant pancreatic cancer cells. Although the molecular mechanism of AHCC for down-regulation of HSP27 is unknown at this time, AHCC can be considered a possible candidate for combinatorial therapy in anticancer drug regimens. It is clear that further studies are needed in order to evaluate AHCC functions. This study supports the potential therapeutic benefits of combinatorial treatment of AHCC and gemcitabine for patients with pancreatic cancer.

Acknowledgements

This work was supported in part by Grants-in-Aid from the Ministry of Education, Science, Sports, and Culture of Japan (no. 24501352 to Yasuhiro Kuramitsu). Immunoblot detection by LAS-1000 was done at the Gene Research Centre of Yamaguchi University. The Authors have declared no conflicts of interest.

  • Received November 14, 2013.
  • Revision received November 29, 2013.
  • Accepted December 2, 2013.
  • Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Raimondi S,
    2. Maisonneuve P,
    3. Lowenfels A
    : Epidemiology of pancreatic cancer. An overview. Nat Rev Gastroenterol Hepatol 6: 699-708, 2009.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Williamson RC
    : Pancreatic cancer: The greatest oncological challenge. Br Med J 13: 445-446, 1988.
    OpenUrl
    1. Gordis L,
    2. Gold EB
    : Epidemiology of pancreatic cancer. World J Surg 8: 808-821, 1984.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Nesse A,
    2. Michl P,
    3. Frese KK,
    4. Fieg C,
    5. Cook N,
    6. Jacobetz MA,
    7. Lolkema MP,
    8. Buchholz M,
    9. Olive KP,
    10. Gress TM,
    11. Tuveson DA
    : Stromal biopsy and therapy in pancreatic cancer. Gut 60: 861-868, 2011.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Burris HA,
    2. Moore MJ III.,
    3. Andersen J,
    4. Green MR,
    5. Rothernberg ML,
    6. Modiano MR,
    7. Cripps MC,
    8. Potenoy RK,
    9. Storniolo AM,
    10. Tarassoff P,
    11. Nelson R,
    12. Dorr FA,
    13. Stephens CD,
    14. Von Hoff DD
    : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 15: 2403-2413, 1997.
    OpenUrlAbstract/FREE Full Text
    1. Tada M,
    2. Arizumi T,
    3. Nakai Y,
    4. Sasaki T,
    5. Kogure H,
    6. Togawa O,
    7. Matsubara S,
    8. Tsujino T,
    9. Hirano K,
    10. Sasahira N,
    11. Isayama H,
    12. Kawabe T,
    13. Omata M
    : Efficacy of gemcitabine for locally advanced pancreatic cancer: Comparison with 5-fluorouracil-based chemoradiotherapy. Chemotherapy 54: 302-308, 2008.
    OpenUrlPubMed
    1. Kim H,
    2. Park JH,
    3. Shin SJ,
    4. Kim MJ,
    5. Bang SJ,
    6. Park NH,
    7. Nah YW,
    8. Nam CW,
    9. Joo KR,
    10. Min YJ
    : Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: A phase II study. Chemotherapy 54: 54-62, 2008.
    OpenUrlPubMed
  5. ↵
    1. Warsame R,
    2. Grothey A
    : Treatment options for advanced pancreatic cancer: A review. Expert Rev Anticancer Ther 12: 1327-1336, 2012.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Shi X,
    2. Liu S,
    3. Kleeff J,
    4. Friess H,
    5. Buchler MW
    : Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 62: 354-362, 2002.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Carmichael J,
    2. Fink U,
    3. Russell RC,
    4. Spittle MF,
    5. Harris AL,
    6. Spiessi G,
    7. Blatter J
    : Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 1-5, 1996.
    OpenUrlPubMed
  8. ↵
    1. Mori-Iwamoto S,
    2. Kuramitsu Y,
    3. Ryozawa S,
    4. Mikuriya K,
    5. Fujimoto M,
    6. Maehara S,
    7. Maehara Y,
    8. Okita K,
    9. Nakamura K,
    10. Sakaida I
    : Proteomics finding heat-shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol 31: 1345-1350, 2007.
    OpenUrlPubMed
  9. ↵
    1. Mori-Iwamoto S,
    2. Kuramitsu Y,
    3. Ryozawa S,
    4. Taba K,
    5. Fujimoto M,
    6. Okita K,
    7. Nakamura K,
    8. Sakaida I
    : A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Mol Med Rep 1: 429-434, 2008.
    OpenUrlPubMed
  10. ↵
    1. Mori-Iwamoto S,
    2. Taba K,
    3. Kuramitsu Y,
    4. Ryozawa S,
    5. Tanaka T,
    6. Maehara S,
    7. Maehara Y,
    8. Okita K,
    9. Nakamura K,
    10. Sakaida I
    : Interferon-γ down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine. Pancreas 38: 224-226, 2009.
    OpenUrlPubMed
  11. ↵
    1. Taba K,
    2. Kuramitsu Y,
    3. Ryozawa S,
    4. Yoshida K,
    5. Tanaka T,
    6. Mori-iwamoto S,
    7. Maehara S,
    8. Maehara Y,
    9. Sakaida I,
    10. Nakamura K
    : KNK437 down-regulates heat-shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine. Chemotherapy 57: 12-16, 2011.
    OpenUrlPubMed
  12. ↵
    1. Kuramitsu Y,
    2. Wang Y,
    3. Taba K,
    4. Suenaga S,
    5. Ryozawa S,
    6. Kaino S,
    7. Sakaida I,
    8. Nakamura K
    : Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells. Anticancer Res 32: 2295-2299, 2012.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Kidd P
    : The use of mushrooms glucans and proteoglycans in cancer treatment. Altern Med Rev 5: 4-27, 2000.
    OpenUrlPubMed
  14. ↵
    1. Shah SK,
    2. Walker PA,
    3. Moore-Olufemi SD,
    4. Kulkrni AD,
    5. Andrassy RJ
    : An evidence-based review of a Lentinula edodes mushroom extract as complementary therapy in the surgical oncology patient. J Parenter Enteral Nutr 35: 449-458, 2011.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Cowawintaweewat S,
    2. Manoromana S,
    3. Sriplung H,
    4. Khyhaprema T,
    5. Tongtawe P,
    6. Tapchaisri P,
    7. Chaicumpa W
    : Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. Asian Pac J Allergy Immunol 24: 33-45, 2006.
    OpenUrlPubMed
    1. Parida DK,
    2. Wakame K,
    3. Nomura T
    : Integrating complimentary and alternative medicine in form of active hexose correlated compound (AHCC) in the management of head and neck cancer patients. Int J Clin Med 2: 588-592, 2011.
    OpenUrl
  16. ↵
    1. Ishizuka R,
    2. Fujii H,
    3. Miura T,
    4. Fukuchi Y,
    5. Tajima K
    : Personalized cancer therapy for stage IV non-small cell lung cancer: Combined use of active hexose correlated compound and genistein concentrated polysaccharide. Pers Med Univers 1: 39-44, 2012.
    OpenUrl
  17. ↵
    1. Maehara S,
    2. Tanaka S,
    3. Shimada M,
    4. Shirabe K,
    5. Saito Y,
    6. Takahashi K,
    7. Maehara Y
    : Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. Int J Cancer 112: 184-189, 2004.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Lowry OH,
    2. Rosebrough NJ,
    3. Farr AL,
    4. Randall RJ
    : Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275, 1951.
    OpenUrlFREE Full Text
  19. ↵
    1. Kuramitsu Y,
    2. Harada T,
    3. Takashima M,
    4. Yokoyama Y,
    5. Hidaka I,
    6. Iizuka N,
    7. Toda T,
    8. Fujimoto M,
    9. Zhang X,
    10. Sakaida I,
    11. Okita K,
    12. Oka M,
    13. Nakamura K
    : Increased expression and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues of patients infected with hepatitis C virus. Electrophoresis 27: 1651-1658, 2006.
    OpenUrlPubMed
    1. Tamesa M,
    2. Kuramitsu Y,
    3. Fujimoto M,
    4. Maeda N,
    5. Nagashima Y,
    6. Tanaka T,
    7. Yamamoto S,
    8. Oka M,
    9. Nakamura K
    : Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis. Electrophoresis 30: 2168-2181, 2009.
    OpenUrlCrossRefPubMed
    1. Kuramitsu Y,
    2. Baron B,
    3. Yoshino S,
    4. Zhang X,
    5. Tanaka T,
    6. Yashiro M,
    7. Hirakawa K,
    8. Oka M,
    9. Nakamura K
    : Proteomic differential display analysis shows up-regulation of 14-4-4 protein sigma in human scirrhous-type gastric carcinoma cells. Anticancer Res 30: 4459-4465, 2010.
    OpenUrlAbstract/FREE Full Text
    1. Kuramitsu Y,
    2. Hayashi E,
    3. Okada F,
    4. Tanaka T,
    5. Zhang X,
    6. Ueyama Y,
    7. Nakamura K
    : Proteomic analysis for nuclear proteins related to tumour malignant progression: A Comparative proteomic study between malignant progressive cells and regressive cells. Anticancer Res 30: 2093-2099, 2010.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Kuramitsu Y,
    2. Takashima M,
    3. Yokoyama Y,
    4. Lizuka N,
    5. Tamesa T,
    6. Akada JK,
    7. Wang Y,
    8. Toda T,
    9. Sakaida I,
    10. Okita K,
    11. Oka M,
    12. Nakamura K
    : Up-regulation of 42 kDa tubulin α-6 chain fragment in well-differentiated hepatocellular carcinoma tissues from patients infected with hepatitis C virus. Anticancer Res 31: 3331-3336, 2011.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Jakob U,
    2. Gaestel M,
    3. Engel K,
    4. Buchner J
    : Small heat-shock proteins are molecular chaperones. J Biol Chem 268: 1517-1520, 1993.
    OpenUrlAbstract/FREE Full Text
    1. Carver JA,
    2. Rekas A,
    3. Thorn DC,
    4. Wilson MR
    : Small heat-shock proteins and clusterin: Intra- and extracellular molecular chaperones with a common mechanism of action and function? IUBMB Life 55: 661-668, 2003.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Bryantsev AL,
    2. Kurchashova SY,
    3. Golyshev SA,
    4. Polyakov VY,
    5. Wunderink HF,
    6. Kanon B,
    7. Budagova KR,
    8. Kabakov AE,
    9. Kampinga HH
    : Regulation of stress-induced intracellular sorting and chaperone function of Hsp27 (HspB1) in mammalian cells. Biochem J 407: 407-417, 2007
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Rane MJ,
    2. Pan Y,
    3. Singh S,
    4. Powell DW,
    5. Wu R,
    6. Cummins T,
    7. Chen Q,
    8. McLeish KR,
    9. Klein JB
    : Heat-shock protein 27 controls apoptosis by regulating Akt activation. J Biol Chem 278: 27828-27835, 2003.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Garrido C,
    2. Bruey JM,
    3. Fromentin A,
    4. Hammann A,
    5. Arrigo AP,
    6. Solary E
    : HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J 13: 2061-2070, 1999.
    OpenUrlAbstract/FREE Full Text
    1. Hansen RK,
    2. Parra I,
    3. Lemieux P,
    4. Oesterreich S,
    5. Hilsenbeck SG,
    6. Fuqua SA
    : HSP27 overexpression inhibits doxorubicininduced apoptosis in human breast cancer cells. Breast Cancer Res Treat 56: 187-196, 1999.
    OpenUrlPubMed
    1. Gibbons NB,
    2. Watson RW,
    3. Coffey RN,
    4. Brady HP,
    5. Fitzpatrick JM
    : Heat-shock proteins inhibit induction of prostate cancer cell apoptosis. Prostate 45: 58-65, 2000.
    OpenUrlCrossRefPubMed
    1. Urbani A,
    2. Poland J,
    3. Bernardini S,
    4. Bellincampi L,
    5. Biroccio A,
    6. Schnölzer M,
    7. Sinha P,
    8. Federici G
    : A proteomic investigation into etoposide chemoresistance of neuroblastoma cell lines. Proteomics 5: 796-804, 2005.
    OpenUrlCrossRefPubMed
    1. Ciocca DR,
    2. Oesterreich S,
    3. Chamness GC,
    4. McGuire WL,
    5. Fuqua SA
    : Biological and clinical implications of heat-shock protein 27,000 (Hsp27): A review. J Natl Cancer Inst 85: 1558-1570, 1993.
    OpenUrlAbstract/FREE Full Text
    1. Cornford PA,
    2. Dodson AR,
    3. Parsons KF,
    4. Desmond AD,
    5. Woolfenden A,
    6. Fordham M,
    7. Neoptolemos JP,
    8. Ke Y,
    9. Foster CS
    : Heat-shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60: 7099-7105, 2000.
    OpenUrlAbstract/FREE Full Text
    1. Romanucci M,
    2. Marinelli A,
    3. Sarli G,
    4. Della Salda L
    : Heat-shock protein expression in canine malignant mammary tumours. BMC Cancer 6: 171, 2006.
    OpenUrlCrossRefPubMed
    1. Bauer K,
    2. Nitsche U,
    3. Slotta-Huspenina J,
    4. Drecoll E,
    5. von Weyherm CH,
    6. Rosenberg R,
    7. Höfler H,
    8. Langer R
    : High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer. Cell Oncol 35: 197-205, 2012.
    OpenUrl
  25. ↵
    1. Kang SH,
    2. Kang KW,
    3. Kim KH,
    4. Kwon B,
    5. Kim SK,
    6. Lee HY,
    7. Kong SY,
    8. Lee ES,
    9. Jang SG,
    10. Yoo BC
    : Up-regulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing HER2 protein stability. BMC Cancer 8: 286, 2008.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Hsu HS,
    2. Lin JH,
    3. Huang WC,
    4. Hsu TW,
    5. Su K,
    6. Chiou SH,
    7. Tsai YT,
    8. Hung SC
    : Chemoresistance of lung cancer stem-like cells depends on activation of Hsp27. Cancer 117: 1516-1528, 2011.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Heinrich JC,
    2. Tuukkanen A,
    3. Schroeder M,
    4. Fahrig T,
    5. Fahrig R
    : RP101 (brivudine) binds to heat-shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients. J Cancer Res Clin Oncol 137: 1349-1361, 2011.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Spierings EL,
    2. Fujii H,
    3. Sun B,
    4. Walshe T
    : A phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. J Nutr Sci Vitaminol 53: 536-539, 2007.
    OpenUrlCrossRefPubMed
    1. Terakawa N,
    2. Matsui Y,
    3. Satoi S,
    4. Yanagimoto H,
    5. Takahashi K,
    6. Yamamoto T,
    7. Yamao J,
    8. Takai S,
    9. Kwon AH,
    10. Kamiyama Y
    : Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: A double-blind, placebo-controlled trial. Nutr Cancer 60: 643-651, 2008.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Matsui Y,
    2. Uhara J,
    3. Satoi S,
    4. Kaibori M,
    5. Yamada H,
    6. Kitade H,
    7. Imamura A,
    8. Takai S,
    9. Kawaguchi Y,
    10. Kwon AH,
    11. Kamiyama Y
    : Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol 37: 78-86, 2002.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Nakamoto D,
    2. Shigama K,
    3. Nishioka H,
    4. Fujii H
    : Active hexose correlated compound (AHCC) alleviates gemcitabine-induced hematological toxicity in non-tumor-bearing mice. Int J Clin Med 3: 361-367, 2012.
    OpenUrl
  31. ↵
    1. Sun B,
    2. Wakame K,
    3. Sato E,
    4. Nishioka H,
    5. Aruoma OI,
    6. Fujii H
    : The effect of active hexose correlated compound in modulating cytosine arabinoside-induced hair loss, and 6-mercaptopurine- and methotrexate-induced liver injury in rodents. Cancer Epidemiol 33: 293-299, 2009.
    OpenUrlPubMed
  32. ↵
    1. Matsushita K,
    2. Kuramitsu Y,
    3. Ohiro Y,
    4. Obata M,
    5. Kobayashi M,
    6. Li YQ,
    7. Hosokawa M
    : Combination therapy of active hexose-correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma. Anticancer drugs 9: 343-350, 1998.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Hirose A,
    2. Sato E,
    3. Fujii H,
    4. Sun B,
    5. Nishioka H,
    6. Aruoma OI
    : The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol 222: 152-158, 2007.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

Anticancer Research: 34 (1)
Anticancer Research
Vol. 34, Issue 1
January 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Active Hexose-correlated Compound Down-regulates HSP27 of Pancreatic Cancer Cells, and Helps the Cytotoxic Effect of Gemcitabine
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Active Hexose-correlated Compound Down-regulates HSP27 of Pancreatic Cancer Cells, and Helps the Cytotoxic Effect of Gemcitabine
SHIGEYUKI SUENAGA, YASUHIRO KURAMITSU, SEIJI KAINO, SHIN-ICHIRO MAEHARA, YOSHIHIKO MAEHARA, ISAO SAKAIDA, KAZUYUKI NAKAMURA
Anticancer Research Jan 2014, 34 (1) 141-146;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Active Hexose-correlated Compound Down-regulates HSP27 of Pancreatic Cancer Cells, and Helps the Cytotoxic Effect of Gemcitabine
SHIGEYUKI SUENAGA, YASUHIRO KURAMITSU, SEIJI KAINO, SHIN-ICHIRO MAEHARA, YOSHIHIKO MAEHARA, ISAO SAKAIDA, KAZUYUKI NAKAMURA
Anticancer Research Jan 2014, 34 (1) 141-146;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • CUB Domain-containing Protein 1 (CDCP1) Is Down-regulated by Active Hexose-correlated Compound in Human Pancreatic Cancer Cells
  • Enzyme-treated Asparagus Extract Down-regulates Heat Shock Protein 27 of Pancreatic Cancer Cells
  • Active Hexose-correlated Compound Down-regulates Heat Shock Factor 1, a Transcription Factor for HSP27, in Gemcitabine-resistant Human Pancreatic Cancer Cells
  • High-mobility Group Box 1 and Mitogen-activated Protein Kinase activated Protein Kinase-2 Are Up-regulated in Gemcitabine-resistant Pancreatic Cancer Cells
  • Google Scholar

More in this TOC Section

  • The Mechanism of the Synergistic Anticancer Effect of CDDP and EPA in the TE1 Cell Line
  • Ephrin Receptor A4 Expression Enhances Migration, Invasion and Neurotropism in Pancreatic Ductal Adenocarcinoma Cells
  • Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model
Show more Experimental Studies

Similar Articles

Keywords

  • Active hexose-correlated compound
  • Heat-shock protein 27
  • pancreatic cancer
  • gemcitabine
Anticancer Research

© 2021 Anticancer Research

Powered by HighWire